Quick Answer
SANGAMO THERAPEUTICS, INC reported Total Assets of $59.75 million for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -41.2% in Total Assets from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $95.62 million | Q3 2011: $88.31 million | Q1 2012: $90.42 million | Q2 2012: $86.31 million | Q3 2012: $81.81 million | Q1 2013: $75.84 million | Q2 2013: $74.20 million | Q3 2013: $140.37 million | Q1 2014: $255.50 million | Q2 2014: $250.84 million | Q3 2014: $247.35 million | Q1 2015: $238.51 million | Q2 2015: $229.95 million | Q3 2015: $232.52 million | Q1 2016: $197.05 million | Q2 2016: $180.91 million | Q3 2016: $164.98 million | Q1 2017: $146.81 million | Q2 2017: $282.99 million | Q3 2017: $269.79 million | Q1 2018: $281.17 million | Q2 2018: $627.73 million | Q3 2018: $606.60 million | Q1 2019: $542.73 million | Q2 2019: $673.48 million | Q3 2019: $640.22 million | Q1 2020: $584.28 million | Q2 2020: $894.66 million | Q3 2020: $963.71 million | Q1 2021: $877.10 million | Q2 2021: $835.36 million | Q3 2021: $772.40 million | Q1 2022: $654.31 million | Q2 2022: $617.13 million | Q3 2022: $593.91 million | Q1 2023: $440.57 million | Q2 2023: $325.07 million | Q3 2023: $219.70 million | Q1 2024: $128.96 million | Q2 2024: $93.01 million | Q3 2024: $111.26 million | Q1 2025: $86.17 million | Q2 2025: $97.56 million | Q3 2025: $88.64 million.
- Over the full 16 years of available data (2010 to 2025), SANGAMO THERAPEUTICS, INC's Total Assets has declined by 5.2%.
- Historical annual values: Fiscal year 2025: $59.75 million | Fiscal year 2024: $101.64 million | Fiscal year 2023: $165.32 million | Fiscal year 2022: $562.51 million | Fiscal year 2021: $721.92 million | Fiscal year 2020: $938.55 million | Fiscal year 2019: $637.52 million | Fiscal year 2018: $590.40 million | Fiscal year 2017: $286.74 million | Fiscal year 2016: $157.89 million | Fiscal year 2015: $217.24 million | Fiscal year 2014: $243.21 million | Fiscal year 2013: $140.84 million | Fiscal year 2012: $82.53 million | Fiscal year 2011: $87.34 million | Fiscal year 2010: $63.00 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: